Abstract:Abstract Background Increased cell apoptosis mediated by P53 or activated autoimmunity was frequent in low-grade MDS especially in 5q-syndrome and those with trisomy 8. However, MDS clonal cells can gradually acquired apoptosis resistance under different stressed conditions. The mechanism of apoptosis resistance is still not fully understood. The polycomb group protein EZH2 as an anti-apoptosis protein drives tumorigenesis. The association of EZH2 with apoptosis resistance of MDS clonal cells is worth further investigating. Objective The objective of this study is to investigate the role of EZH2 in the mechanism of apoptosis resistance of MDS. Methods The expression of EZH2 protein was analyzed by flow cytometry in 71 MDS patients. EZH2-targeted genes were identified through an integrated analysis of gene expression microarray analysis in MDS patients and cell line. EZH2-targeted genes were confirmed through chromatin immunoprecipitation and luciferase reporter gene assay. Cell functional and metabolic experiments were also performed. Results We observed upregulation of the EZH2 expression in the patients with low-grade MDS especially in the individuals with trisomy 8 although downregulation in the patients with high-grade MDS. Based on the distinct EZH2 expression pattern, we identified an EZH2-targeted gene PSAT1, a serine biosynthetic critical enzyme through an integrated analysis of gene expression microarray analysis in MDS patients and cell line. Functionally, EZH2 can directly activate PSAT1 transcription by binding to its promoter and this effect is independent of its H3K27me3 enzymatic activity in vitro. Expanded sample analysis revealed the overexpression of PSAT1 in MDS patients especially in low-grade MDS. High expression of PSAT1 was associated with severe cytopenias, iron overload and activation of T lymphocytes-mediated autoimmunity. In vitro, overexpression of PSAT1 led to a significant proliferation advantage in the MDS and leukemia cell lines. Overexpression of PSAT1 could also downregulate apoptosis sensitivity to inflammatory cytokines and cytotoxic agents in vitro. However, knockdown of PSAT1 resulted in reduced cell growth capacity and increased the apoptosis sensitivity to cytotoxic agents. Further cancer metabolic experiments showed that overexpression of PSAT1 inhibited the ROS generation and induced an increase in glucose uptake, lactate and ATP production, which may make MDS clonal cells adaptive in the stress-related apoptosis environment. Conclusion EZH2/PSAT1 axis-mediated serine biosynthetic pathway is activated in low-grade MDS, which may confer MDS clonal cells growth advantages and resistance to stress-related apoptosis. Disclosures No relevant conflicts of interest to declare.

Overexpression of BMI1 confers clonal cells resistance to apoptosis and contributes to adverse prognosis in myelodysplastic syndrome.

BMI1 Regulates Multiple Myeloma-Associated Macrophage’s Pro-Myeloma Functions

Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes.

Clinical Significance of Cytogenetic and Molecular Genetic Abnormalities in 634 Chinese Patients with Myelodysplastic Syndromes

[Clinical and Cytogenetic Study of Chromosome 1 Abnormality in Myelodysplastic Syndrome].

Cytogenetic Abnormalities Predict Disease Progression in Primary Myelodysplastic Syndrome: A Multicentric Study in 508 Chinese Patients.

Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring

Bmi-1 Is Related To Proliferation, Survival And Poor Prognosis In Pancreatic Cancer

Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes

The Non-Cell-autonomous Function of ID1 Promotes AML Progression Via ANGPTL7 from the Microenvironment.

BMI-1, a promising therapeutic target for human cancer.

Crosstalk Between Circbmi1 and Mir-338-5p/id4 Inhibits Acute Myeloid Leukemia Progression

Crosstalk between circBMI1 and miR-338-5p/ID4 inhibits AML progression

BMI1 activates P-glycoorotein via transcription repression of <i>miR</i>-<i>3682</i>-<i>3p</i> and enhances chemoresistance of bladdder cancer cell

Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia

Lower BCL11B Expression is Associated with Adverse Clinical Outcome for Patients with Myelodysplastic Syndrome

High Co-Expression of PDCD1/TIGIT/CD47/KIR3DL2 in Bone Marrow is Associated with Poor Prognosis for Patients with Myelodysplastic Syndrome.

Retracted: EBF1 Gene Promotes the Proliferation and Inhibits the Apoptosis of Bone Marrow CD34+ Cells in Patients with Myelodysplastic Syndrome Through Negative Regulation of Mitogen‐activated Protein Kinase Axis

Ezh2-Mediated Activation of Serine Biosynthetic Pathway is Critical for Resistance of Clonal Cells to Stress-Related Apoptosis in Low-Grade Myelodysplastic Syndrome

Overexpression of BMI‐1 is Associated with Poor Prognosis in Cervical Cancer

Bmi1 Polycomb Group Protein Acts As A Master Switch For Growth And Death Of Tumor Cells: Regulates Tcf4-Transcriptional Factor-Induced Bcl2 Signaling